Orteronel

Drug Profile

Orteronel

Alternative Names: TAK-700

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Takeda
  • Developer Millennium; Swiss Group for Clinical Cancer Research; Takeda Oncology
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Naphthalenes; Pyrrolidines; Small molecules
  • Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Jun 2014 Discontinued - Phase-III for Prostate cancer (hormone-refractory disease; first or second line therapy) in countries worldwide (PO)
  • 16 May 2014 Efficacy and adverse events data from the phase III ELM-PC 4 trial for Prostate cancer (combination therapy, first-line therapy, hormone refractory, metastatic disease) released by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top